$25.32
2.45%
Nasdaq, Apr 21, 07:49 pm CET
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Moderna Stock price

$24.72
-10.00 28.80% 1M
-30.11 54.92% 6M
-16.87 40.56% YTD
-78.73 76.11% 1Y
-130.04 84.03% 3Y
-22.14 47.25% 5Y
+6.12 32.88% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.48 1.89%
ISIN
US60770K1079
Symbol
MRNA
Sector
Industry

Key metrics

Market capitalization $9.54b
Enterprise Value $3.26b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.01
P/S ratio (TTM) P/S ratio 2.95
P/B ratio (TTM) P/B ratio 0.88
Revenue growth (TTM) Revenue growth -52.75%
Revenue (TTM) Revenue $3.24b
EBIT (operating result TTM) EBIT $-3.95b
Free Cash Flow (TTM) Free Cash Flow $-4.06b
Cash position $7.03b
EPS (TTM) EPS $-9.28
P/E forward negative
P/S forward 4.51
EV/Sales forward 1.54
Short interest 17.89%
Show more

Is Moderna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Moderna Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Moderna forecast:

5x Buy
18%
19x Hold
68%
4x Sell
14%

Analyst Opinions

28 Analysts have issued a Moderna forecast:

Buy
18%
Hold
68%
Sell
14%

Financial data from Moderna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
3,236 3,236
53% 53%
100%
- Direct Costs 1,653 1,653
69% 69%
51%
1,583 1,583
3% 3%
49%
- Selling and Administrative Expenses 985 985
6% 6%
30%
- Research and Development Expense 4,354 4,354
3% 3%
135%
-3,756 -3,756
4% 4%
-116%
- Depreciation and Amortization 189 189
69% 69%
6%
EBIT (Operating Income) EBIT -3,945 -3,945
7% 7%
-122%
Net Profit -3,561 -3,561
24% 24%
-110%

In millions USD.

Don't miss a Thing! We will send you all news about Moderna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Moderna Stock News

Positive
The Motley Fool
about 23 hours ago
In the early days of the COVID-19 pandemic, Moderna (MRNA -1.89%) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies, the biotech brought in billions of dollars in annual earnings and saw its stock price jump more than 2,300% from January 2020 through early August of 2021.
Neutral
Investors Business Daily
11 days ago
Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might "go wild" on biotech stocks.
Neutral
Accesswire
11 days ago
CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report its first quarter 2025 financial results, and provide a corporate update.
More Moderna News

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Stéphane Bancel
Employees 5,800
Founded 2010
Website www.modernatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today